시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 비만세포증 의약품 시장 보고서(2025년)
Mastocytosis Drug Global Market Report 2025
상품코드 : 1769649
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,305,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,114,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,923,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비만세포증 의약품 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안의 예상 성장은 희귀 질환 치료에 대한 강조가 높아지고, 맞춤형 의약품이 등장하고, 알레르기 및 면역계 질환의 발병률이 증가하고, 보조 요법의 사용이 확대되고, 개발 중인 의약품의 파이프라인이 확대되고 있기 때문으로 볼 수 있습니다. 이 기간 동안 예상되는 주요 동향으로는 의학 연구의 진보, 표적 치료 옵션의 개발, 유전 연구의 발전, 병용 요법 접근법의 채택, 약물 전달 기술의 혁신 등이 있습니다.

희귀 질환에 대한 투자가 증가함에 따라 향후 몇 년 동안 비만세포증 의약품 시장이 성장할 것으로 예상됩니다. 희귀 질환은 인구의 소수, 일반적으로 미국에서는 20만 명 미만, 유럽에서는 2,000명 중 1명 미만에 영향을 미치는 의학적 상태입니다. 이 분야에 대한 투자 증가는 주로 희귀 의약품 지정, 시장 독점권 연장, 세금 공제 등 규제 인센티브의 확대에 기인하며, 이러한 인센티브는 제약 회사의 개발 위험을 낮추고 수익성을 개선하는 데 도움이 됩니다. 비만세포증 치료제는 비만세포증의 증상을 관리하는 데 도움이 될 뿐만 아니라 유사한 면역 또는 세포 경로를 공유하는 다른 희귀 질환의 치료법 발전에도 기여하는 표적 치료법을 제공합니다. 예를 들어(2024년) 4월, 미국에 본사를 둔 비영리 단체인 Global Genes는 2024년 1분기에 희귀 질환 의약품 개발에 주력하는 기업들이 공개 주식 및 채무 금융을 통해 71억 달러의 자금을 조달했다고 보고했습니다. 이는 2023년 같은 기간에 조달한 18억 달러에 비해 307% 증가한 수치입니다. 그 결과, 희귀 질환에 대한 투자 증가가 비만세포증 의약품 시장의 확장을 촉진하고 있습니다.

비만세포증 의약품 시장의 선도 기업들은 치료 효과를 높이고 진행성 비만 세포 장애 환자를 위한 표적 솔루션을 제공하기 위해 티로신 키나아제 억제제와 같은 혁신적인 치료법 개발에 집중하고 있습니다. 티로신 키나아제 억제제는 비정상적인 세포 성장에 관여하는 효소를 차단하는 약물입니다. 비만세포증의 경우, 이러한 의약품은 비만 세포의 과도한 성장을 억제하여 발진 및 염증과 같은 증상을 완화합니다. 예를 들어, 2023년 5월, 미국에 본사를 둔 생명공학 기업인 Blueprint Medicines Corporation은 미 식품의약국(FDA)으로부터 ISM(indolent systemic mastocytosis, 저급성 전신성 비만세포증) 성인 환자를 치료하기 위한 Ayvakit(avapritinib)의 승인을 받았습니다. 이 승인은 마스트 세포 과다 생산으로 특징지어지는 희귀하고 만성적인 질환인 ISM 관리에 있어 중요한 진전을 의미합니다. Ayvakit은 ISM 환자에게 흔히 발견되는 KIT D816V 변이를 표적하는 선택적 억제제로, 증상 관리 및 질환 관리에 초점을 맞춘 치료 옵션을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

HBR
영문 목차

영문목차

Mastocytosis drugs are medications used to treat mastocytosis, a rare disorder marked by the abnormal buildup of mast cells in the skin, bone marrow, and internal organs. These medications are designed to manage symptoms, suppress mast cell activity, or address more aggressive forms of the condition.

The primary types of mastocytosis drugs include antihistamines, corticosteroids, and mast cell stabilizers. Antihistamines serve as first-line treatments by alleviating symptoms through the prevention of histamine from binding to its receptors during allergic responses. These drugs are used to manage conditions such as systemic mastocytosis, cutaneous mastocytosis, and mast cell activation syndrome. They can be administered orally, intravenously, or subcutaneously. Distribution occurs through hospital pharmacies, online pharmacies, retail stores, and other channels. Key end users include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The mastocytosis drug market research report is one of a series of new reports from The Business Research Company that provides mastocytosis drug market statistics, including the mastocytosis drug industry global market size, regional shares, competitors with the mastocytosis drug market share, detailed mastocytosis drug market segments, market trends, and opportunities, and any further data you may need to thrive in the mastocytosis drug industry. This mastocytosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mastocytosis drug market size has grown strongly in recent years. It will grow from $1.07 billion in 2024 to $1.17 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historic period can be attributed to an aging population, a rising prevalence of blood cancers, increased utilization of biologic and immunotherapies, growing healthcare spending, and a higher incidence of mastocytosis.

The mastocytosis drug market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The projected growth during the forecast period can be attributed to a growing emphasis on rare disease treatments, the emergence of personalized medicine, an increasing incidence of allergies and immune system disorders, greater use of supportive therapies, and an expanding pipeline of drugs in development. Key trends anticipated during this period include progress in medical research, the development of targeted treatment options, advancements in genetic research, the adoption of combination therapy approaches, and innovations in drug delivery technologies.

The rising investment in rare diseases is expected to drive the growth of the mastocytosis drug market in the coming years. Rare diseases are medical conditions that impact a small portion of the population-typically fewer than 200,000 individuals in the United States or fewer than 1 in 2,000 people in Europe. Increased investment in this area is largely fueled by growing regulatory incentives such as orphan drug designations, extended market exclusivity, and tax credits, which help lower development risks and improve profitability for pharmaceutical companies. Mastocytosis drugs provide targeted treatment that not only helps manage mastocytosis symptoms but also contributes to the advancement of therapies for other rare diseases sharing similar immune or cellular pathways. For example, in April 2024, Global Genes, a US-based nonprofit organization, reported that in the first quarter of 2024, companies focused on rare disease drug development raised $7.1 billion through public equity and debt financings-a 307% increase compared to the $1.8 billion raised during the same period in 2023. As a result, rising investment in rare diseases is fueling the expansion of the mastocytosis drug market.

Leading companies in the mastocytosis drug market are concentrating on developing innovative treatments such as tyrosine kinase inhibitors to enhance therapeutic effectiveness and offer targeted solutions for patients with advanced mast cell disorders. Tyrosine kinase inhibitors are medications that block enzymes involved in abnormal cell growth. In the context of mastocytosis, these drugs work by inhibiting the excessive growth of mast cells, thereby reducing symptoms like rashes and inflammation. For example, in May 2023, Blueprint Medicines Corporation, a biotechnology company based in the U.S., received approval from the U.S. Food and Drug Administration for Ayvakit (avapritinib) to treat adults with indolent systemic mastocytosis (ISM). This approval represents a significant step forward in managing ISM, a rare and chronic condition marked by the overproduction of mast cells. Ayvakit is a selective inhibitor targeting the KIT D816V mutation, which is commonly found in ISM patients, providing a focused treatment option for symptom control and disease management.

In May 2024, Incyte Corporation, a biopharmaceutical company based in the United States, acquired Escient Pharmaceuticals for approximately $750 million. This acquisition is intended to bolster Incyte's Inflammation and Autoimmunity (IAI) pipeline by incorporating Escient Pharmaceuticals' first-in-class oral MRGPR antagonists, thereby enhancing its ability to develop novel therapies for serious immune and neuro-immune conditions. Escient Pharmaceuticals is a U.S.-based clinical-stage biotechnology company focused on developing EP262, a first-in-class oral MRGPRX2 antagonist aimed at treating mast cell-mediated diseases.

Major players in the mastocytosis drug market are Pfizer Inc., Johnson & Johnson, Bayer AG, Sanofi S.A., Novartis AG, GSK plc, Teva Pharmaceutical Industries Limited, Alcon Inc., Bausch Health Companies Inc., Genentech Inc., Lupin Limited, Blueprint Medicines Corporation, Don Valley Pharma (Pvt.) Ltd., Vivan Life Sciences Private Limited, AB Science S.A., Medoz Pharmaceutical Private Limited, Zumax Biocare Private Limited, Hi-Cure Biotech Private Limited, Zenomed Healthcare Private Limited, Biosynth AG.

North America was the largest region in the mastocytosis drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mastocytosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the mastocytosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mastocytosis drug market also includes sales of antihistamines, leukotriene receptor antagonists, corticosteroids, tyrosine kinase inhibitors (TKIs), and epinephrine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mastocytosis Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mastocytosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for mastocytosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mastocytosis drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Mastocytosis Drug Market Characteristics

3. Mastocytosis Drug Market Trends And Strategies

4. Mastocytosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Mastocytosis Drug Growth Analysis And Strategic Analysis Framework

6. Mastocytosis Drug Market Segmentation

7. Mastocytosis Drug Market Regional And Country Analysis

8. Asia-Pacific Mastocytosis Drug Market

9. China Mastocytosis Drug Market

10. India Mastocytosis Drug Market

11. Japan Mastocytosis Drug Market

12. Australia Mastocytosis Drug Market

13. Indonesia Mastocytosis Drug Market

14. South Korea Mastocytosis Drug Market

15. Western Europe Mastocytosis Drug Market

16. UK Mastocytosis Drug Market

17. Germany Mastocytosis Drug Market

18. France Mastocytosis Drug Market

19. Italy Mastocytosis Drug Market

20. Spain Mastocytosis Drug Market

21. Eastern Europe Mastocytosis Drug Market

22. Russia Mastocytosis Drug Market

23. North America Mastocytosis Drug Market

24. USA Mastocytosis Drug Market

25. Canada Mastocytosis Drug Market

26. South America Mastocytosis Drug Market

27. Brazil Mastocytosis Drug Market

28. Middle East Mastocytosis Drug Market

29. Africa Mastocytosis Drug Market

30. Mastocytosis Drug Market Competitive Landscape And Company Profiles

31. Mastocytosis Drug Market Other Major And Innovative Companies

32. Global Mastocytosis Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Mastocytosis Drug Market

34. Recent Developments In The Mastocytosis Drug Market

35. Mastocytosis Drug Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기